Search

Your search keyword '"Collovà, E."' showing total 6 results
Start Over Author "Collovà, E." Search Limiters Peer Reviewed
6 results on '"Collovà, E."'

1. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Author

Cicchiello, F., Riva, F., Vallini, I., Mazza, M., Bonfadini, C., Bordin, E., Canicattì, M., Cappuccio, F., Collovà, E., De Angelis, C., Desorte, R., Donati, S., Drudi, G., Galanti, D., Mocerino, C., Orlando, L., Pellegrino, B., Pizzuti, L., Ridolfi, C., Rocca, A., Sarti, D., Spagnoletti, I., Tinari, N., Vandone, A., Vizzini, L., Cazzaniga, M.E., Pinotti, G., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Fiorentini, G., Fontana, A., Gambaro, A.R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Melegari, E., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M.G., Schintu, M.G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M.R., Vici, P., Clivio, L., and Torri, V.

Published
2019
Full Text
View/download PDF

3. SIOG2021-0013* - Evaluation of dexamethasone (DEX)-sparing regimens, administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in older patients receiving...

Author

Celio, L., Cortinovis, D., Cogoni, A.A., Cavanna, L., Martelli, O., Carnio, S., Collovà, E., Bertolini, F., Petrelli, F., Cassano, A., Chiari, R., Zanelli, F., Pisconti, S., Vittimberga, I., Letizia, A., Misino, A., Gernone, A., Bonizzoni, E., Pilotto, S., and De Placido, S.

Published
2021
Full Text
View/download PDF

4. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Author

Zucali, P.A., Simonelli, M., Michetti, G., Tiseo, M., Ceresoli, G.L., Collovà, E., Follador, A., Lo Dico, M., Moretti, A., De Vincenzo, F., Lorenzi, E., Perrino, M., Giordano, L., Farina, G., Santoro, A., and Garassino, M.

Subjects
*CANCER chemotherapy, *MESOTHELIOMA, *RETROSPECTIVE studies, *MEDICAL care surveys, *CANCER patients, *CISPLATIN, *HEALTH outcome assessment, *CANCER invasiveness, *THERAPEUTICS
Abstract

Abstract: The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients’ characteristics: median-age 64 years (range: 36–85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression≥12months (TTP≥12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p =0.017) and FL-TTP≥12 (OR: 3.50; p =0.006). PFS was related to younger age (<65years) (HR: 0.70; p =0.045), ECOG-PS0 (HR: 0.67; p =0.022), and FL-TTP≥12 (HR: 0.45; p <0.001). OS was significantly related to ECOG-PS0 (HR: 0.43; p <0.001) and to FL-TTP≥12 (HR: 0.54; p =0.005). In pemetrexed pre-treated patients, re-treatment with a pemetrexed/platinum combination significantly reduced the risk-of-death than pemetrexed alone (HR: 0.11; p <0.001). In conclusion, SL-chemotherapy seems to be active in MPM-patients, particularly in younger patients with ECOG-PS0 and prolonged TTP after FL-pemetrexed-based chemotherapy. In selected patients, re-challenge with pemetrexed-based regimens, preferentially associated with platinum-compound, appears to be an option for SL-setting. Considering the important limitations of this study, due to retrospective nature and the possible selection bias, prospective clinical trials are warranted to clarify these issues. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

5. 1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial.

Author

Celio, L., Cortinovis, D., Cogoni, A., Cavanna, L., Martelli, O., Carnio, S., Collovà, E., Bertolini, F., Petrelli, F., Cassano, A., Chiari, R., Zanelli, F., Vittimberga, I., Letizia, A., Misino, A., Silvestris, F., Bonizzoni, E., Pilotto, S., De Placido, S., and Bria, E.

Subjects
*CISPLATIN, *VOMITING, *DEXAMETHASONE
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results